Take part in PSC clinical trials and research studies

ORBCEL-C™

This study is investigating the safety and activity of the use of ORBCEL-C™ in the treatment of patients with primary sclerosing cholangitis, rheumatoid arthritis, lupus nephritis and Crohn’s disease.

Find out more

ClinicalTrials.gov Identifier: NCT05525520

The PACIFIC Study is seeking adults diagnosed with PSC or PBC to evaluate the investigational drug for cholestatic itch.

Find out more

ClinicalTrials.gov Identifier: NCT05627362

The ELMWOOD Study is seeking adults diagnosed with PSC to evaluate the safety and efficacy of Elafibranor.

Find out more

The Liver Unit at University Hospitals Birmingham (Queen Elizabeth Hospital) is leading this study.

Find out more

PLN-74809

ClinicalTrials.gov Identifier: NCT04480840

This study is investigating the safety, tolerability, and pharmacokinetics of PLN-74809 in patients with PSC.

EARLY RESULTS

MORE ABOUT THE TRIAL

Selected mesenchymal stromal cells to reduce liver inflammation

ISRCTN Identifier: ISRCTN73586959

The aim of this study is to investigate whether patients with primary sclerosing cholangitis (PSC) or autoimmune hepatitis (AIH) can be safely and effectively treated with a therapy called mesenchymal stromal cells (MSC). This study is also referred to as the 'MERLIN' trial.

Fully recruited.

Find out more

Fully recruited

Find out more

This study is fully recruited.

MuM-PreDiCT is a study about care during pregnancy, birth and after birth.

NorUrsodeoxycholic Acid in the Treatment of PSC

EudraCT Number: 2016-003367-19

The aim of this study is to compare norursodeoxycholic acid (NorUrso, NorUDCA) with placebo in the treatment of primary sclerosing cholangitis.

NOW FULLY RECRUITED IN THE UK (June 2022)

Find out more

Online study recruiting now.

Compensation provided for time spent sharing your experience with cholestatic pruritus (itch associated with liver disease)

Paternally Inherited Phenotypes in Cholestasis Study - (PIP-C)

ClinicalTrials.gov Identifier: NCT03337074

This study is investigating whether cholestatic liver diseases such as PSC can impact the structure and function of sperm. This is important because changes to the sperm can affect the health of the children conceived from those sperm. In this study, the health of 16 – 25 year-old children of fathers with cholestatic liver diseases such as PSC is also being investigated.

The study has 2 arms, the Sperm Epigenome arm and the Outcomes arm. Each participant can decide if they are eligible/would like to take part in one or in both arms of the study.

In the Sperm Epigenome arm, the structure and function of sperm from men with PSC and other cholestatic liver disorders will be investigated and compared to the structure and function of sperm from healthy men.

In the Outcomes arm, basic health parameters in fathers who had PSC or another cholestatic liver disease either before or after their child was conceived will be investigated, as well as basic health parameters in their child when they are aged between 16 and 25 years old.

UK Locations

• King's College Hospital, London
• Guy's Hospital NHS Foundation Trust, London
• Queen Elizabeth Hospital, Birmingham

Contact information

Chief Investigator: Professor Catherine Williamson (catherine.williamson@kcl.ac.uk)
Trial Manager: Sonia Serrano (Sonia.Serrano@gstt.nhs.uk)

Find out more

On hold until further notice because of COVID-19

Vancomycin

ClinicalTrials.gov Identifier: NCT05376228

This study is investigating vancomycin in PSC. It has now recruited all participants into the trial.

Find out more

CM-101

ClinicalTrials.gov Identifier: NCT04595825

This study is fully recruited.

RESULTS

Find out more